DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2238562/wall-street-analysts-see-cvs-health-cvs-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2238562 Mar 11, 2024 - According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.rttnews.com/story.aspx?Id=3431229 Mar 11, 2024 - Following the notable downturn seen over the course of last Friday's session, stocks are likely to see further downside in early trading on Monday. The major index futures are currently pointing to a lower open for the markets. Uncertainty about the outlook for interest rates may weigh on the markets ahead of the release of key inflation data in the coming days. 0

https://seekingalpha.com/news/4077833-delta-ceo-sees-delay-for-boeing-737-max-10-deliveries-until-2027-bloomberg?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news Mar 10, 2024 - Delta Air Lines expects delays in the delivery of Boeing 737 MAX 10 aircraft to as late as 2027 due to safety reviews, CEO Ed Bastian says. 0

https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says?source=feed_sector_healthcare Mar 10, 2024 - Cantor Fitzgerald sees a strong year for oncology M&A as major drugmakers look to replenish pipelines ahead of steep patent cliffs for top-selling products. Read more here. 0

https://seekingalpha.com/article/4677114-s-and-p-500-earnings-still-seeing-upward-revisions-for-s-and-p-500-estimates?source=feed_all_articles Mar 08, 2024 - Oracle, Lennar and Adobe are the only names that will be of interest next week, in terms of companies reporting earnings. 0

https://seekingalpha.com/news/4077751-stifel-downgrades-alx-oncology-to-hold-sees-evorpacept-as-fully-valued?source=feed_sector_healthcare Mar 08, 2024 - Stifel downgraded ALX Oncology (ALXO) to hold, stating it sees the company’s CD47 blocker drug evorpacept as fully valued for the HER2+ gastric cancer opportunity. Read more here. 0

https://www.entrepreneur.com/starting-a-business/6-design-tips-to-make-your-brand-stand-out-in-competitive/470074 Mar 08, 2024 - We live in a time when brands are more visible and visual than ever. Here, six founders explain how they created brand design that stands out. 0

https://seekingalpha.com/news/4077692-novo-nordisk-sees-launching-new-obesity-drugs-before-wegovy-patent-expires?source=feed_sector_healthcare Mar 08, 2024 - Novo Nordisk (NVO) reportedly plans to launch its next-generation obesity drugs, Cagrisema and amycretin, ahead of the expiration of its patent for Wegovy. Read more here. 0

https://www.zacks.com/stock/news/2238228/new-york-community-nycb-cuts-dividend-sees-deposit-outflow?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2238228 Mar 08, 2024 - New York Community (NYCB) slashes the quarterly dividend by 80% to a penny to improve liquidity after witnessing a 5% drop in its deposits since the 2023 end through Mar 5, 2024. 0

https://www.zacks.com/stock/news/2237968/wall-street-analysts-see-symbotic-inc-sym-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2237968 Mar 08, 2024 - Based on the average brokerage recommendation (ABR), Symbotic Inc. (SYM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying? 0